Last reviewed · How we verify

OPTI-FREE® RepleniSH®

Massachusetts Eye and Ear Infirmary · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

OPTI-FREE® RepleniSH® is a Small molecule drug developed by Massachusetts Eye and Ear Infirmary. It is currently FDA-approved.

OPTI-FREE RepleniSH is a contact lens care product used in conjunction with silicone hydrogel soft contact lenses, such as ACUVUE VITA, to manage conditions like myopia and refractive errors associated with contact lens wear. The exact mechanism of OPTI-FREE RepleniSH is unknown.

At a glance

Generic nameOPTI-FREE® RepleniSH®
SponsorMassachusetts Eye and Ear Infirmary
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about OPTI-FREE® RepleniSH®

What is OPTI-FREE® RepleniSH®?

OPTI-FREE® RepleniSH® is a Small molecule drug developed by Massachusetts Eye and Ear Infirmary.

Who makes OPTI-FREE® RepleniSH®?

OPTI-FREE® RepleniSH® is developed and marketed by Massachusetts Eye and Ear Infirmary (see full Massachusetts Eye and Ear Infirmary pipeline at /company/massachusetts-eye-and-ear-infirmary).

What development phase is OPTI-FREE® RepleniSH® in?

OPTI-FREE® RepleniSH® is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing